Pharmacogenetic Testing Market Report 2026

Pharmacogenetic Testing Market Overview

• Pharmacogenetic Testing market size has reached to $14.33 billion in 2025 • Expected to grow to $29.55 billion in 2030 at a compound annual growth rate (CAGR) of 15.5% • Growth Driver: Impact Of Personalized Medicine On The Growth Of The Pharmacogenetic Testing Market • Market Trend: Advancements In Prescription-Based Pharmacogenetic Testing • Asia-Pacific was the largest region and fastest growing region.

What Is Covered Under Pharmacogenetic Testing Market?

Pharmacogenetic testing is a type of genetic testing that examines how an individual's genetic makeup influences their response to specific medications, helping to tailor drug treatments for better efficacy and reduced side effects. This personalized approach enhances patient care by tailoring therapies based on genetic profiles. It is widely used in fields such as oncology, psychology, and cardiology. The main types of pharmacogenetic testing are whole genome sequencing, whole exome sequencing, array-based tests, and single gene tests. Whole genome sequencing is a comprehensive method for analyzing the entire genome of an organism. It involves sequencing all of the DNA in a single test, providing a complete picture of an individual's genetic makeup. Droug type includes prescription drugs, nutraceuticals, recreational drugs, herbal supplements, vitamins, and over-the-counter medications for different therapeutic areas such as cardiology, gastroenterology, anesthesiology, genomics, endocrinology, immunology and hypersensitivity, dermatology, gynecology, oncology, and others. These are distributed through hospital pharmacies, retail pharmacies, mail-order pharmacies, and direct-to-customer services and are used by various end users, such as healthcare providers, pharmaceutical and biotechnology companies, centers and academic institutes, and others.

What Is The Pharmacogenetic Testing Market Growth Forecast?

The pharmacogenetic testing market size is expected to see rapid growth in the next few years. It will grow to $29.55 billion in 2030 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to growth of precision healthcare, expansion of direct-to-consumer testing, integration with electronic health records, increasing regulatory support, rising investment in genomics research. Major trends in the forecast period include rising adoption of personalized medicine, increasing use of genetic testing in drug selection, expansion of oncology and cardiology applications, growing demand for precision diagnostics, integration of pharmacogenomics in clinical practice.

Global Pharmacogenetic Testing Market Segmentation

1) By Type: Whole Genome Sequencing, Whole Exome Sequencing, Array-Based Tests, Single Gene Tests 2) By Drug Type: Prescription Drugs, Nutraceuticals, Recreational Drugs, Herbal Supplements, Vitamins, Over-The-Counter Medications 3) By Therapeutic Area: Cardiology, Gastroenterology, Anesthesiology, Genomics, Endocrinology, Immunology And Hypersensitivity, Dermatology, Gynecology, Oncology, Other Therapeutic Areas 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacies, Mail-Order Pharmacies, Direct-to-Customer Services 5) By End User: Healthcare Providers, Pharmaceutical And Biotechnology Companies, Centers And Academic Institutes, Other End Users Subsegments: 1) By Whole Genome Sequencing: Illumina Sequencing, Ion Torrent Sequencing, Pacific Biosciences Sequencing, Oxford Nanopore Sequencing 2) By Whole Exome Sequencing: Capture-Based Exome Sequencing, Targeted Enrichment Exome Sequencing, Hybridization-Based Exome Sequencing 3) By Array-Based Tests: SNP Array Testing, Expression Array Testing, Copy Number Variation Array Testing 4) By Single Gene Tests: Targeted Gene Panels, Mutation Detection Tests, Sequencing Of Specific Genes

What Is The Driver Of The Pharmacogenetic Testing Market?

The increasing demand for personalized medicine is expected to propel the growth of the pharmacogenetic testing market going forward. Personalized medicine, or precision medicine, refers to a healthcare approach that tailors treatments and medical decisions to an individual’s unique genetic, biological, and lifestyle characteristics. The demand for personalized medicine is rising due to its ability to improve treatment outcomes, support early detection, and enhance cost-effectiveness in patient care. The pharmacogenetic testing market supports personalized medicine by analyzing an individual's genetic profile to predict drug responses, enabling optimized treatment selection and reducing the risk of adverse reactions. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to 6 approvals in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the pharmacogenetic testing industry.

Key Players In The Global Pharmacogenetic Testing Market

Major companies operating in the pharmacogenetic testing market are CVS Health Corporation, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Eurofins Scientific Inc., Bio-Rad Laboratories, Precision Medicine Advsiors, Azenta Life Sciences, Fulgent Genetics, Pacific Biosciences of California Inc., Castle Biosciences, 23andMe Holding Co., Helix Inc., Genomind Inc., MD Labs, Sonic Genetics, AutoGenomics Inc., LabClinics SA, Gene By Gene Ltd., Xcode Life Sciences, YouScript, RxGenomix LLC

Global Pharmacogenetic Testing Market Trends and Insights

Major companies operating in the pharmacogenetics testing market are focusing on developing advanced pharmacogenomics testing services, such as prescription-based pharmacogenetic testing, to enhance medication safety, improve treatment precision, and support personalized therapeutic decision-making. Prescription-based pharmacogenetic testing refers to genetic analyses ordered by licensed healthcare providers to examine how an individual’s genetic makeup influences their response to specific medications, allowing clinicians to optimize drug selection and dosing while reducing the likelihood of adverse drug reactions. For instance, in May 2023, UCSF, a US-based healthcare organization, launched its pharmacogenomics testing service designed to improve the precision of medical treatments, providing healthcare professionals with genetic insights that help tailor drug therapies to each patient’s unique profile, strengthen drug efficacy, and minimize the risk of harmful side effects.

What Are Latest Mergers And Acquisitions In The Pharmacogenetic Testing Market?

In May 2023, HealthŌme, a US-based company specializing in advanced genetic testing and personalized medicine solutions, acquired Kailos Genetics for an undisclosed amount. This acquisition strengthens HealthŌme’s personalized medicine portfolio by integrating Kailos Genetics’ advanced genomic technologies and pharmacogenetic capabilities. It further enhances HealthŌme’s ability to deliver comprehensive precision-testing solutions through expanded expertise in genomic analysis and individualized treatment insights. Kailos Genetics is a US-based company that provides pharmacogenetic testing services through its Inspexion platform.

Regional Insights

Asia-Pacific was the largest region in the pharmacogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pharmacogenetic Testing Market?

The pharmacogenetic testing market consists of revenues earned by entities by providing services such as predicting drug efficacy, guiding dosage selection, and preventing adverse drug reactions. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmacogenetic testing market also includes sales of gene panels, deoxyribonucleic acid (DNA) sequencers, and home testing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pharmacogenetic Testing Market Report 2026?

The pharmacogenetic testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pharmacogenetic testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.